Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CTR002
MIFTS: 60

Cataract

Categories: Cardiovascular diseases, Eye diseases, Fetal diseases, Genetic diseases, Mental diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Oral diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Cataract

About this section

MalaCards integrated aliases for Cataract:

Name: Cataract 11 75 28 53 5 41 43 14 38 33
Cataracts 14 63
Cat - [cataract] 33
Lens Opacities 33
Cataract Form 33
Lens Opacity 33

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Metabolic diseases Fetal diseases
Anatomical: Eye diseases Neuronal diseases Nephrological diseases Skin diseases Cardiovascular diseases Oral diseases Mental diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:83
ICD9CM 34 366.8
MeSH 43 D002386
SNOMED-CT 68 193620000
UMLS 71 C0029531
Sources

Summaries for Cataract

About this section

PubMed Health : 63 Cataracts: A cataract is an eye condition in which the lens of the eye becomes cloudy. This causes vision to worsen, making it especially difficult to see fine details clearly. Some people’s vision is only slightly affected, whereas others might lose their eyesight very quickly. How it progresses will depend on things like the exact type of cataract. The word “cataract” comes from the Greek word for “waterfall” because in the past it was believed that the blurring was caused by a fluid in the eye. Cataracts mostly affect people over 50, and the risk increases with age: About 20 out of 100 people between the ages of 65 and 74 have a cataract. And more than 50 out of 100 people over the age of 74 are affected. Cataracts are the main cause of blindness in developing countries. The number of people who go blind from cataracts is considerably lower in industrialized countries due to the availability of effective surgery. Cataract surgery involves removing the cloudy eye lens and replacing it with an artificial lens. It is one of the most common surgical procedures performed in Germany, where about 800,000 people have cataract surgery every year.

MalaCards based summary: Cataract, also known as cataracts, is related to cataract 1, multiple types and senile cataract. An important gene associated with Cataract is CRYBB3 (Crystallin Beta B3), and among its related pathways/superpathways is 1q21.1 copy number variation syndrome. The drugs Cyclopentolate and Atropine have been mentioned in the context of this disorder. Affiliated tissues include Eye, endothelial and cortex, and related phenotype is vision/eye.

MedlinePlus: 41 A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are: Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision Frequent prescription changes in your eye wear Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute

Disease Ontology: 11 A lens disease characterized by clouding of the lens inside the eye which leads to a decrease in vision.

Wikipedia: 75 A cataract is a cloudy area in the lens of the eye that leads to a decrease in vision. Cataracts often... more...
Sources

Related Diseases for Cataract

About this section

Diseases in the Cataract family:

Cataract 32, Multiple Types Cataract 7
Cataract 8, Multiple Types Cataract 4, Multiple Types
Cataract 29 Cataract 42
Cataract 20, Multiple Types Cataract 1, Multiple Types
Cataract 30, Multiple Types Cataract 41
Cataract 6, Multiple Types Cataract 5, Multiple Types
Cataract 40 Cataract 10, Multiple Types
Cataract 24 Cataract 3, Multiple Types
Cataract 14, Multiple Types Cataract 9, Multiple Types
Cataract 2, Multiple Types Cataract 31, Multiple Types
Cataract 25 Cataract 26, Multiple Types
Cataract 27 Cataract 28
Cataract 35 Cataract 22, Multiple Types
Cataract 18 Cataract 21, Multiple Types
Cataract 23, Multiple Types Cataract 11, Multiple Types
Cataract 33, Multiple Types Cataract 17, Multiple Types
Cataract 12, Multiple Types Cataract 47
Cataract 34, Multiple Types Cataract 16, Multiple Types
Cataract 36 Cataract 37
Cataract 38 Cataract 39, Multiple Types
Cataract 15, Multiple Types Cataract 19, Multiple Types
Cataract 43 Cataract 44
Cataract 45 Cataract 48
Cataract 49 Cataract 30
Cataract 33 Cataract Congenital Autosomal Dominant

Diseases related to Cataract via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2010)
# Related Disease Score Top Affiliating Genes
1 cataract 1, multiple types 33.3 GJA8 GJA3
2 senile cataract 33.3 GJA8 GJA3 CRYGD CRYBB3 CRYAA
3 cataract 7 33.3 EPHA2 CRYGD CCA1
4 cataract 9, multiple types 33.2 GJA8 CRYAA
5 cataract 24 33.2 CTAA2 CRYBB3 CRYAA
6 cataract microcornea syndrome 33.2 GJA8 CRYGD CRYAA
7 nance-horan syndrome 33.2 LIM2 GJA8 GJA3 CRYGD CRYBB3 CRYAA
8 cataract 44 33.1 LIM2 GJA8 EPHA2 CRYAA
9 cataract 14, multiple types 33.1 GJA8 GJA3
10 cataract 30, multiple types 33.1 GJA8 GJA3 CRYGD
11 posterior polar cataract 33.0 GJA8 GJA3 EPHA2 CRYAA
12 cataract 28 33.0 LIM2 CTRCT28 CRYAA
13 mature cataract 32.9 GJA8 CRYGD CRYAA
14 cataract 29 32.9 CTRCT29 CRYGD
15 aniridia 1 32.8 GJA8 GJA3 EPHA2-AS1 EPHA2 CRYGD CRYBB3
16 galactosemia ii 32.8 LIM2 CRYBB3 CRYAA
17 amblyopia 32.7 LIM2 GJA8 GJA3 CRYGD CRYBB3 CRYAA
18 early-onset nuclear cataract 32.4 GJA8 GJA3 EPHA2 CRYGD CRYBB3 CRYAA
19 deprivation amblyopia 32.2 CRYGD CRYBB3 CRYAA
20 early-onset posterior polar cataract 32.1 GJA3 EPHA2
21 early-onset lamellar cataract 32.0 CRYGD CRYAA
22 marinesco-sjogren syndrome 32.0 SIL1 CRYAA
23 coloboma of macula 31.9 RHO GJA8 CRYAA
24 presbyopia 31.8 LIM2 GJA8 GJA3 CRYGD CRYAA
25 oculodentodigital dysplasia 31.3 GJA8 GJA3
26 anterior segment dysgenesis 31.3 GJA8 GJA3 CRYGD CRYBB3 CRYAA
27 lens disease 31.1 WRN SIL1 RHO GJA8 GJA3 CRYGD
28 leukocoria 31.0 CRYGD CRYAA
29 hallermann-streiff syndrome 30.9 GJA3 CRYAA
30 retinal perforation 30.9 RHO CRYAA
31 axenfeld-rieger syndrome, type 3 30.3 LIM2 CRYAA
32 sclerocornea 30.3 GJA8 CRYAA
33 congenital aphakia 30.2 GJA8 CRYAA
34 coloboma of optic nerve 30.0 GJA8 CRYAA
35 retinal ischemia 30.0 RHO CRYAA
36 vitreous disease 29.9 RHO CRYAA
37 retinal vascular occlusion 29.7 RHO CRYAA
38 cataract 4, multiple types 11.7
39 hyperferritinemia with or without cataract 11.6
40 leukodystrophy, hypomyelinating, 5 11.6
41 optic atrophy 3, autosomal dominant 11.6
42 cataract 21, multiple types 11.6
43 cataract 6, multiple types 11.6
44 cataract 11, multiple types 11.6
45 cataract 3, multiple types 11.6
46 cataract 40 11.6
47 cataract 2, multiple types 11.6
48 cataract 47 11.5
49 cataract 16, multiple types 11.5
50 cataract 22, multiple types 11.5

Graphical network of the top 20 diseases related to Cataract:



Diseases related to Cataract
Sources

Symptoms & Phenotypes for Cataract

About this section

MGI Mouse Phenotypes related to Cataract:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.28 CRYAA CRYGD EPHA2 GJA3 GJA8 IARS2
Sources

Drugs & Therapeutics for Cataract

About this section

PubMed Health treatment related to Cataract: 63

Some people can compensate for the vision loss, temporarily or even in the longer term, by wearing glasses or contact lenses . There are no medications for the treatment of cataracts . The only effective treatment is surgery . Cataract surgery involves removing the cloudy lens and replacing it with a new, artificial lens. The lens capsule – an elastic membrane surrounding the lens of the eye – is left in the eye during surgery. Only the inner core and the outer cortex of the lens are broken up into small pieces using ultrasound. The pieces are then sucked out of the eye through a small cut. This procedure, called phacoemulsification , is the standard technique in Germany and some other countries. Once the lens has been removed, an artificial lens is implanted into the lens capsule. Whether and when surgery is an appropriate treatment option is very much a personal decision. The extent to which vision loss is affecting someone’s life will play a very important role. Another factor to consider is the presence of other (eye ) conditions, which could affect the outcome of cataract surgery .

Drugs for Cataract (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 281)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclopentolate Approved Phase 4 512-15-2 2905
2
Atropine Approved, Vet_approved Phase 4 101-31-5, 5908-99-6, 51-55-8 3661 154417 174174
3
Dipivefrin Approved Phase 4 52365-63-6 3105
4
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
5
Homatropine Approved Phase 4 87-00-3
6
Moxifloxacin Approved, Investigational Phase 4 186826-86-8, 354812-41-2, 151096-09-2 152946
7
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
8
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
10
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
11
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
12
Loteprednol etabonate Approved, Experimental Phase 4 82034-46-6, 129260-79-3 22227703 9865442 444025
13
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294
14
Dinoprostone Approved Phase 4 363-24-6, 7448-03-5 5280360
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
16
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
17
Ofloxacin Approved Phase 4 82419-36-1 4583
18
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
19
Tropicamide Approved, Investigational Phase 4 1508-75-4 5593
20
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
21
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
22
Gatifloxacin Approved, Investigational, Withdrawn Phase 4 112811-59-3 5379
23
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
24
Reviparin Approved, Investigational Phase 4 9041-08-1
25
Besifloxacin Approved Phase 4 141388-76-3 22743624 10178705
26
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
27
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
28
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
29
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
30
Azithromycin Approved Phase 4 83905-01-5 447043
31
Vancomycin Approved Phase 4 1404-90-6 14969
32 Orange Approved Phase 4
33
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
34
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
35
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
36
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
37
Aflibercept Approved Phase 4 862111-32-8 124490314
38
Bevacizumab Approved, Investigational Phase 4 216974-75-3 135329020
39
Ranibizumab Approved Phase 4 347396-82-1
40
Framycetin Approved, Experimental, Vet_approved Phase 4 1404-04-2, 119-04-0, 3947-65-7 413349 8378
41
Polymyxin B Approved, Vet_approved Phase 4 1405-20-5, 1404-26-8 4868
42
Cianidanol Approved, Withdrawn Phase 4 154-23-4 9064
43
Bromfenac Approved, Withdrawn Phase 4 91714-94-2 60726
44
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
45
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
46
Cefuroxime Approved Phase 4 55268-75-2 5479529
47
Racephedrine Approved, Experimental Phase 4 299-42-3, 90-82-4, 90-81-3 5032 9294 7028
48
Phenylephrine Approved Phase 4 59-42-7 6041
49
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
50
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068

Interventional clinical trials:

(show top 50) (show all 1385)
# Name Status NCT ID Phase Drugs
1 Evaluation of Efficacy in the Resolution of Post-Operative Inflammation and Pain in Patients Receiving Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery Unknown status NCT04316936 Phase 4 Omidria;Dextenza (dexamethasone ophthalmic insert) 0.4mg;Dexycu, 9% Intraocular Suspension;Prednisolone Acetate 1%
2 Topical 0,09% Bromfenac for Intraoperative Miosis and Pain Reduction in Femtosecond Laser-assisted Cataract Surgery Unknown status NCT03831984 Phase 4 0,09% Bromfenac;0,1% sodium hyaluronate
3 A Prospective Trial Evaluating a Intracanalicular Insert Delivery System Compared to Traditional Topical Drops in Controlling Post-operative Pain and inFlammation in Subjects Undergoing Sequential Bilateral Cataract Surgery Unknown status NCT04205916 Phase 4 Dexamethasone
4 DEXTENZA VS. PREDNISOLONE ACETATE 1% in the Incidence of Pseudophakic Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery Unknown status NCT04362241 Phase 4 Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
5 A Randomized Controlled Clinical Trial aSsessing the Efficacy of DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert When Placed Within the Upper Eye Lid Canaliculus in Comparison to the Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With Posterior Chamber Intraocular Lens Implant (CE/PCIOL). Unknown status NCT04592081 Phase 4 Dextenza 0.4Mg Ophthalmic Insert
6 The Effect of Pretreated Gabapentin on Hyeralgesia Occurring in the Second Operation in Staged Bilateral Cataract Surgery Unknown status NCT02127853 Phase 4 gabapentin;placebo
7 Relevance of Eye Dominance in the Selection of Patients Suitable for Treatment With Monovision After Cataract Surgery Unknown status NCT01382641 Phase 4
8 A Study to Assess the Clinical Outcomes of Surgical Phaco Segmentation Techniques in Patients Undergoing Cataract Surgery Unknown status NCT02843594 Phase 4
9 Visual Performance Following Implantation of a Hydrophobic Aspheric Monofocal Intraocular Lens Unknown status NCT03819582 Phase 4
10 Effect of Anti-inflammatory Topical Prednisolone Acetate 1%, Nepafenac of 0.1% and Ketorolac Tromethamine 0.4% in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
11 A Randomised Intra-patient Comparison of Closed Loop and Plate Haptic Toric, Aspheric, Aberration Neutral, Hydrophilic Acrylic Intraocular Lenses in Patients With Bilateral Astigmatism Unknown status NCT02264457 Phase 4
12 Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens Unknown status NCT02378636 Phase 4
13 Combined Phacoemulsification and Glaucoma Implant Surgery Versus Combined Phacoemulsification and Trabeculectomy: A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
14 Combined Subconjunctival Atropine and Intracameral Epinephrine Injection for Pupil Dilation in Phacoemulsification Under Peribulbar Anesthesia. Unknown status NCT03638726 Phase 4 Atropine sulfate and epinephrine;Topical cyclopentolate and phenylephrine
15 Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia Unknown status NCT01554761 Phase 4
16 AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL Unknown status NCT01278420 Phase 4
17 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
18 Pre-surgical Ocular Surface Treatment With Intracanalicular Dexamethasone Insert and Effect on Intraocular Lens Measurement Accuracy - The PRECISION Study Unknown status NCT04530864 Phase 4 Dextenza 0.4Mg Ophthalmic Insert
19 Co-Axial Micro-incision Cataract Surgery(C-MICS) Versus Standard Co-Axial Small Incision Cataract Surgery Using the Stellaris Enhancement System Completed NCT01261975 Phase 4
20 A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery Completed NCT01769313 Phase 4
21 Intraoperative Dexamethasone Implant (Ozurdex®) Improves Outcome of Cataract Surgery in Patients With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
22 Randomised Study of Propofol Versus Placebo for Sedation During Cataract Surgery Under Topical Anesthesia Completed NCT02771912 Phase 4 Propofol;Placebo
23 Dexmedetomidine vs. Propofol for Monitored Anesthesia Care During Cataract Completed NCT00786370 Phase 4 dexmedetomidine;Propofol;Dexemedetomidine
24 To Compare the Ability of DiscoVisc® Ophthalmic Viscosurgical Device (OVD) to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery. Completed NCT00763360 Phase 4 Healon;Amvisc Plus
25 The Reggio Emilia Study on Bromfenac for Patients With PseudoEXfoliation Syndrome Undergoing Cataract Surgery: the REPEX Study Completed NCT02137161 Phase 4 Dexamethasone+Tobramycin eye drop;Bromfenac eye drop
26 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4 Sodium Carboxymethylcellulose;Levofloxacin;Prednisolone
27 A Prospective, Post-Market-Clinical-Follow-Up Study to Investigate the Long-term (3 Months) Safety of Femtosecond-laser Assisted Cataract Surgery Completed NCT02023437 Phase 4
28 A Prospective, Randomized Single-Masked Clinical Trial Comparing OCT and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care Completed NCT00698724 Phase 4 Xibrom, and Optive;Xibrom and Pred Forte
29 Efficacy and Safety of Difluprednate Ophthalmic Emulsion vs. a Fixed-Combination of Prednisolone Acetate - Phenylephrine Ophthalmic Suspension on Post-operative Inflammation Following Cataract Surgery. Completed NCT04631315 Phase 4 Difluprednate Ophthalmic Emulsion 0.05%;Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution
30 Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplicated Cataract Surgery Completed NCT00494494 Phase 4 Standard Care;nepafenac
31 Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients Completed NCT01859702 Phase 4 Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
32 Effect of Cequa Treatment on Accuracy of Pre-operative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery Completed NCT04342988 Phase 4 Cequa
33 The Effect of Preoperative Topical Ketorolac 0.45% on Aqueous Cytokine Levels and Macular Thickness in Diabetic and Non Diabetic Patients Undergoing Cataract Surgery Completed NCT02646072 Phase 4 Ketorolac tromethamine ophthalmic solution 0.45%
34 Prospective, Randomized Study Comparing Effect on Wound Healing of Vigamox (Moxifloxacin 0.5% Ophthalmic Solution) and Cravit (Levofloxacin 0.5% Ophthalmic Solution) Administered Post-Surgically in Patients Undergoing Cataract Extraction Completed NCT00840580 Phase 4 Moxifloxacin 0.5% ophthalmic solution (Vigamox);Levofloxacin 0.5% ophthalmic solution (Cravit)
35 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects Completed NCT00469690 Phase 4 Acular, Xibrom
36 A Multi-centre, Multi-surgeon, Randomized, Controlled, Prospective, Post-Market-Clinical-Follow-Up Study to Investigate the Impact of Cataract Grade on the Efficacy and Safety of Femtosecond-laser Assisted Lens Fragmentation Procedure Completed NCT01971177 Phase 4
37 Phase IV Study_Prospective Evaluation of the Effectiveness of the Femtosecond Laser-assisted Refractive Astigmatic Keratotomy Following the Cataract Surgery. Completed NCT01885780 Phase 4
38 Bromfenac 0.09% Versus Dexamethasone 0.1% Ophthalmic Solutions to Reduce Inflammation After Cataract Surgery Completed NCT03317847 Phase 4 Bromfenac 0.09 % Ophthalmic Solution;Dexamethasone 0.1% ophthalmic suspension
39 Fuchs' Endothelial Dystrophy and Cataract Surgery: Can Torsional Phacoemulsification Decrease the Risk for Corneal Decompensation Completed NCT00781027 Phase 4
40 Protein Profile of Immunoregulatory Factors in Diabetic Cataract Completed NCT01832311 Phase 4 Ketorolac
41 Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial Completed NCT03886779 Phase 4 Bromfenac;Nepafenac
42 The Effects of Intraocular Phenylephrine/Ketorolac Infusion on Retinal Thickness and Macular Edema in Cataract Surgery Completed NCT03864133 Phase 4 Omidria
43 The D3 Study: Drug Delivery vs Drops - A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1% in Controlling Post-operative Pain and Inflammation in Patients Undergoing Sequential Cataract Surgery Completed NCT04273282 Phase 4 Dexycu intracameral dexamethasone;Prednisolone Acetate
44 Effectiveness of Liposomial Ozonized-Oil on Ocular Microbial Flora Before Cataract Surgery Completed NCT04087733 Phase 4 OZODROP
45 Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery Completed NCT00758199 Phase 4 Bromfenac;Moxifloxacin hydrochloride;Prednisolone Acetate
46 Therapeutic Variables in Cataract Surgery Completed NCT00407017 Phase 4 Gatifloxacin;Ketorolac LS;Pred Forte;Moxifloxacin;Nepafenac;EconoPred Plus
47 Randomized Clinical Trial Evaluating Anti-inflammatory Effect of Low Molecular-Weight Heparin in Pediatric Cataract and Intraocular Lens Surgery Completed NCT00986076 Phase 4 Enoxaparin;Balanced Salt Solution
48 Parallel-group Study of Ocular Penetration of Peri-operative Topically Administered Fluoroquinolones With Cataract Surgery Completed NCT00924729 Phase 4 Moxifloxacin 0.5% ophthalmic solution;Besifloxacin 0.6% ophthalmic suspension
49 A Comparative Study of Use of Cyclosporin Eye Before Cataract Surgery for the Prevention of Dry Eye Completed NCT04426240 Phase 4 Cyclosporine microemulsion
50 Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery Completed NCT02819908 Phase 4 Imprimis Dropless;Imprimis Less Drops

Search NIH Clinical Center for Cataract

Cochrane evidence based reviews: cataract

Sources

Genetic Tests for Cataract

About this section

Genetic tests related to Cataract:

# Genetic test Affiliating Genes
1 Cataract 28
Sources

Anatomical Context for Cataract

About this section

Organs/tissues related to Cataract:

MalaCards : Eye, Endothelial, Cortex, Retina, Bone Marrow, Brain, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cataract:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Lens Affected by disease
Sources

Publications for Cataract

About this section

Articles related to Cataract:

(show top 50) (show all 40301)
# Title Authors PMID Year
1
Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome. 62 5
25130867 2014
2
An evaluation of the efficacy of a supplemental computer-based tutorial to enhance the informed consent process for cataract surgery: an exploratory randomized clinical study. 62 41
36368980 2022
3
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
4
Combined phacoemulsification surgery and intravitreal triamcinolone injection versus stand-alone surgery in patients with type 2 diabetes: a prospective randomized trial. 41
36401233 2022
5
Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)-Randomized Controlled Trial. 41
36422204 2022
6
In vivo lens deficiency of the R49C alphaA-crystallin mutant. 53 62
20188090 2010
7
Cerebrotendinous xanthomatosis (CTX): an association of pulverulent cataracts and pseudo-dominant developmental delay in a family with a splice site mutation in CYP27A1--a case report. 53 62
20450308 2010
8
A novel human CRYGD mutation in a juvenile autosomal dominant cataract. 53 62
20508808 2010
9
Hyperferritinaemia-cataract syndrome: worldwide mutations and phenotype of an increasingly diagnosed genetic disorder. 53 62
20511138 2010
10
Oxidative stress markers in patients with primary open-angle glaucoma. 53 62
20373896 2010
11
A novel mutation in the major intrinsic protein (MIP) associated with autosomal dominant congenital cataracts in a Chinese family. 53 62
20361015 2010
12
HTS-Compatible Patient-Derived Cell-Based Assay to Identify Small Molecule Modulators of Aberrant Splicing in Myotonic Dystrophy Type 1. 53 62
20502647 2010
13
Later retinal degeneration following childhood surgical aphakia in a family with recessive CRYAB mutation (p.R56W). 53 62
20141356 2010
14
[Progress in pathogenic genes and their functions of congenital cataract]. 53 62
20450675 2010
15
Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA. 53 62
19967157 2009
16
A novel GJA8 mutation (p.I31T) causing autosomal dominant congenital cataract in a Chinese family. 53 62
20019893 2009
17
[Hereditary hyperferritinemia cataract syndrome--the first family in Germany]. 53 62
19994473 2009
18
Glucose-6-phosphate dehydrogenase (G6PD) deficiency and senile cataract in a Sardinian male population, Italy. 53 62
19995205 2009
19
Mutations in MYH9 exons 1, 16, 26, and 30 are infrequently found in Japanese patients with nonsyndromic deafness. 53 62
19645626 2009
20
[Mutation analysis of the PAX6 gene in a family with congenital aniridia and cataract]. 53 62
19806578 2009
21
A novel mutation (F71L) in alphaA-crystallin with defective chaperone-like function associated with age-related cataract. 53 62
19595763 2009
22
Synergistic effects of metal ion and the pre-senile cataract-causing G98R alphaA-crystallin: self-aggregation propensities and chaperone activity. 53 62
19862354 2009
23
Effects of alpha-crystallin on lens cell function and cataract pathology. 53 62
19860667 2009
24
Age-related cataracts and Prdx6: correlation between severity of lens opacity, age and the level of Prdx 6 expression. 53 62
19429582 2009
25
A novel gammaD-crystallin mutation causes mild changes in protein properties but leads to congenital coralliform cataract. 53 62
19668596 2009
26
Founder heterozygous P23T CRYGD mutation associated with cerulean (and coralliform) cataract in 2 Saudi families. 53 62
19633732 2009
27
Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma. 53 62
19551670 2009
28
EPHA2 is associated with age-related cortical cataract in mice and humans. 53 62
19649315 2009
29
An alphaA-crystallin gene mutation, Arg12Cys, causing inherited cataract-microcornea exhibits an altered heat-shock response. 53 62
19503744 2009
30
Aquaporins: translating bench research to human disease. 53 62
19448080 2009
31
Bilateral cataract in a subject carrying a C to A transition in the L ferritin promoter region. 53 62
19254706 2009
32
Initiation codon mutation in betaB1-crystallin (CRYBB1) associated with autosomal recessive nuclear pulverulent cataract. 53 62
19461930 2009
33
Identification of a novel CRYAB mutation associated with autosomal recessive juvenile cataract in a Saudi family. 53 62
19461931 2009
34
Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. 53 62
19437594 2009
35
Deletion of mouse MsrA results in HBO-induced cataract: MsrA repairs mitochondrial cytochrome c. 53 62
19461988 2009
36
NMR study of the cataract-linked P23T mutant of human gammaD-crystallin shows minor changes in hydrophobic patches that reflect its retrograde solubility. 53 62
19275895 2009
37
Aquaporin water channels in mammals. 53 62
19085041 2009
38
Removal of Hsf4 leads to cataract development in mice through down-regulation of gamma S-crystallin and Bfsp expression. 53 62
19224648 2009
39
Mitochondrial function and redox control in the aging eye: role of MsrA and other repair systems in cataract and macular degenerations. 53 62
18588875 2009
40
11p Microdeletion including WT1 but not PAX6, presenting with cataract, mental retardation, genital abnormalities and seizures: a case report. 53 62
19222835 2009
41
Genetics of crystallins: cataract and beyond. 53 62
19007775 2009
42
N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population. 53 62
19503764 2009
43
Autosomal-dominant cerulean cataract in a chinese family associated with gene conversion mutation in beta-B2-crystallin. 53 62
19321936 2009
44
A new locus for congenital cataract, microcornea, microphthalmia, and atypical iris coloboma maps to chromosome 2. 53 62
19004499 2009
45
Novel mutation in the gamma-S crystallin gene causing autosomal dominant cataract. 53 62
19262743 2009
46
Disulfide cross-links in the interaction of a cataract-linked alphaA-crystallin mutant with betaB1-crystallin. 53 62
19071118 2009
47
Oxidative stress markers in aqueous humor of patients with senile cataracts. 53 62
19172468 2009
48
Structural function of MIP/aquaporin 0 in the eye lens; genetic defects lead to congenital inherited cataracts. 53 62
19096783 2009
49
Synergistic effect of osmotic and oxidative stress in slow-developing cataract formation. 53 62
18760274 2008
50
A missense mutation in ALDH18A1, encoding Delta1-pyrroline-5-carboxylate synthase (P5CS), causes an autosomal recessive neurocutaneous syndrome. 53 62
18478038 2008
Sources

Variations for Cataract

About this section

ClinVar genetic disease variations for Cataract:

5 (show top 50) (show all 97)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IARS2 NM_018060.4(IARS2):c.2726C>T (p.Pro909Leu) SNV Pathogenic
 156553 rs587783070 GRCh37: 1:220316451-220316451
GRCh38: 1:220143109-220143109
2 RHO NM_000539.3(RHO):c.891C>G (p.Ser297Arg) SNV Pathogenic
 523376 rs142285818 GRCh37: 3:129251570-129251570
GRCh38: 3:129532727-129532727
3 LIM2 NM_001161748.2(LIM2):c.388C>T (p.Arg130Cys) SNV Pathogenic
 625113 rs1568480054 GRCh37: 19:51883831-51883831
GRCh38: 19:51380577-51380577
4 EPHA2, EPHA2-AS1 NM_004431.5(EPHA2):c.41G>A (p.Trp14Ter) SNV Pathogenic
 1341682 GRCh37: 1:16482387-16482387
GRCh38: 1:16155892-16155892
5 SIL1 NC_000005.10:g.139189727_139201554del DEL Pathogenic
Pathogenic
 812923 GRCh37: 5:138525416-138537243
GRCh38:
6 CRYBB3 NM_004076.5(CRYBB3):c.467G>A (p.Gly156Glu) SNV Pathogenic
 1704644 GRCh37: 22:25601326-25601326
GRCh38: 22:25205359-25205359
7 COL5A1 NM_000093.5(COL5A1):c.608G>T (p.Gly203Val) SNV Likely Pathogenic
 523328 rs1554781700 GRCh37: 9:137593133-137593133
GRCh38: 9:134701287-134701287
8 COL18A1, SLC19A1 NM_001379500.1(COL18A1):c.3448C>T (p.Arg1150Ter) SNV Likely Pathogenic
 373961 rs1057518802 GRCh37: 21:46929468-46929468
GRCh38: 21:45509554-45509554
9 WRN NM_000553.6(WRN):c.724+1G>T SNV Likely Pathogenic
 523380 rs1339616347 GRCh37: 8:30925844-30925844
GRCh38: 8:31068328-31068328
10 COL18A1 NM_001379500.1(COL18A1):c.929-2A>G SNV Likely Pathogenic
 373962 rs765919785 GRCh37: 21:46897323-46897323
GRCh38: 21:45477409-45477409
11 COPB1 NM_001144061.2(COPB1):c.957+1G>T SNV Likely Pathogenic
 996016 rs1850695885 GRCh37: 11:14504577-14504577
GRCh38: 11:14483031-14483031
12 COPB1 NM_001144061.2(COPB1):c.1651T>G (p.Phe551Val) SNV Likely Pathogenic
 996037 rs1850476947 GRCh37: 11:14496127-14496127
GRCh38: 11:14474581-14474581
13 PITX2 NM_000325.6(PITX2):c.*176A>T SNV Uncertain Significance
 347296 rs567517676 GRCh37: 4:111539105-111539105
GRCh38: 4:110617949-110617949
14 PITX2 NM_000325.6(PITX2):c.*373GTT[1] MICROSAT Uncertain Significance
 347292 rs886059004 GRCh37: 4:111538903-111538905
GRCh38: 4:110617747-110617749
15 EPM2A NM_005670.4(EPM2A):c.*1691G>A SNV Uncertain Significance
 523391 rs750320097 GRCh37: 6:145946861-145946861
GRCh38: 6:145625725-145625725
16 TALDO1 NM_006755.2(TALDO1):c.328A>G (p.Arg110Gly) SNV Uncertain Significance
 523493 rs766745943 GRCh37: 11:759056-759056
GRCh38: 11:759056-759056
17 MIP NM_012064.4(MIP):c.*1237_*1238dup DUP Uncertain Significance
 309864 rs111463603 GRCh37: 12:56843825-56843826
GRCh38: 12:56450041-56450042
18 MIP NM_012064.4(MIP):c.*148dup DUP Uncertain Significance
 309881 rs35639464 GRCh37: 12:56844915-56844916
GRCh38: 12:56451131-56451132
19 MIP NM_012064.4(MIP):c.*1777dup DUP Uncertain Significance
 309861 rs886049688 GRCh37: 12:56843286-56843287
GRCh38: 12:56449502-56449503
20 MIP NM_012064.4(MIP):c.*132del DEL Uncertain Significance
 309882 rs886049691 GRCh37: 12:56844932-56844932
GRCh38: 12:56451148-56451148
21 HSF4 NM_001374675.1(HSF4):c.*30del DEL Uncertain Significance
 320192 rs756298250 GRCh37: 16:67203717-67203717
GRCh38: 16:67169814-67169814
22 PITX2 NM_000325.6(PITX2):c.412-7C>T SNV Uncertain Significance
 899414 rs762349019 GRCh37: 4:111539851-111539851
GRCh38: 4:110618695-110618695
23 PITX2 NM_000325.6(PITX2):c.*173G>A SNV Uncertain Significance
 900360 rs1728830475 GRCh37: 4:111539108-111539108
GRCh38: 4:110617952-110617952
24 PITX2 NM_000325.6(PITX2):c.695G>A (p.Ser232Asn) SNV Uncertain Significance
 900415 rs746908680 GRCh37: 4:111539561-111539561
GRCh38: 4:110618405-110618405
25 PITX2 NM_000325.6(PITX2):c.282G>T (p.Arg94=) SNV Uncertain Significance
 900537 rs768386257 GRCh37: 4:111542449-111542449
GRCh38: 4:110621293-110621293
26 PITX2 NM_000325.6(PITX2):c.*696A>C SNV Uncertain Significance
 901346 rs1728803615 GRCh37: 4:111538585-111538585
GRCh38: 4:110617429-110617429
27 PITX2 NM_000325.6(PITX2):c.*687A>G SNV Uncertain Significance
 901347 rs185925533 GRCh37: 4:111538594-111538594
GRCh38: 4:110617438-110617438
28 PITX2 NM_000325.6(PITX2):c.*107A>C SNV Uncertain Significance
 901514 rs752553102 GRCh37: 4:111539174-111539174
GRCh38: 4:110618018-110618018
29 PITX2 NM_000325.6(PITX2):c.*264A>C SNV Uncertain Significance
 347295 rs886059006 GRCh37: 4:111539017-111539017
GRCh38: 4:110617861-110617861
30 PITX2 NM_000325.6(PITX2):c.*522T>C SNV Uncertain Significance
 347290 rs188349821 GRCh37: 4:111538759-111538759
GRCh38: 4:110617603-110617603
31 PITX2 NM_000325.6(PITX2):c.*611A>G SNV Uncertain Significance
 347288 rs886059002 GRCh37: 4:111538670-111538670
GRCh38: 4:110617514-110617514
32 PITX2 NM_000325.6(PITX2):c.*370G>C SNV Uncertain Significance
 347293 rs886059005 GRCh37: 4:111538911-111538911
GRCh38: 4:110617755-110617755
33 PITX2 NM_000325.6(PITX2):c.*572T>C SNV Uncertain Significance
 347289 rs886059003 GRCh37: 4:111538709-111538709
GRCh38: 4:110617553-110617553
34 PITX2 NM_000325.6(PITX2):c.412-11del DEL Uncertain Significance
 347299 rs886059007 GRCh37: 4:111539855-111539855
GRCh38: 4:110618699-110618699
35 PITX2 NM_000325.6(PITX2):c.*440C>T SNV Uncertain Significance
 902850 rs1301785358 GRCh37: 4:111538841-111538841
GRCh38: 4:110617685-110617685
36 PITX2 NM_000325.6(PITX2):c.*119T>A SNV Uncertain Significance
 347297 rs765040142 GRCh37: 4:111539162-111539162
GRCh38: 4:110618006-110618006
37 CRYGD, LOC100507443 NM_006891.3(CRYGD):c.-80A>C SNV Uncertain Significance
 333880 rs886055528 GRCh37: 2:208989277-208989277
GRCh38: 2:208124553-208124553
38 EPM2A NM_005670.4(EPM2A):c.376A>G (p.Ile126Val) SNV Uncertain Significance
 167038 rs150452237 GRCh37: 6:146007358-146007358
GRCh38: 6:145686222-145686222
39 PITX2 NM_153427.3(PITX2):c.-40G>A SNV Uncertain Significance
 899457 rs942688607 GRCh37: 4:111557966-111557966
GRCh38: 4:110636810-110636810
40 PITX2 NM_153427.3(PITX2):c.-53G>A SNV Uncertain Significance
 899458 rs1388707841 GRCh37: 4:111557979-111557979
GRCh38: 4:110636823-110636823
41 PITX2 NM_153427.2(PITX2):c.-270A>G SNV Uncertain Significance
 899520 rs1163979542 GRCh37: 4:111558196-111558196
GRCh38: 4:110637040-110637040
42 PITX2 NM_153427.2(PITX2):c.-436G>C SNV Uncertain Significance
 899597 rs1026660025 GRCh37: 4:111558362-111558362
GRCh38: 4:110637206-110637206
43 PITX2 NM_153427.2(PITX2):c.-501T>G SNV Uncertain Significance
 899665 rs915152120 GRCh37: 4:111558427-111558427
GRCh38: 4:110637271-110637271
44 PITX2 NM_153427.2(PITX2):c.-966A>G SNV Uncertain Significance
 899731 rs1049702206 GRCh37: 4:111558892-111558892
GRCh38: 4:110637736-110637736
45 PITX2 NM_153427.2(PITX2):c.-1078C>A SNV Uncertain Significance
 899796 rs1309981396 GRCh37: 4:111559004-111559004
GRCh38: 4:110637848-110637848
46 XDH NM_000379.4(XDH):c.1172C>T (p.Pro391Leu) SNV Uncertain Significance
 598996 rs1558697792 GRCh37: 2:31602803-31602803
GRCh38: 2:31379937-31379937
47 XDH NM_000379.4(XDH):c.3647C>A (p.Pro1216His) SNV Uncertain Significance
 335760 rs143981573 GRCh37: 2:31562482-31562482
GRCh38: 2:31339616-31339616
48 PITX2 NM_153427.2(PITX2):c.-1421G>C SNV Uncertain Significance
 899913 rs758425186 GRCh37: 4:111563111-111563111
GRCh38: 4:110641955-110641955
49 PITX2 NM_153427.2(PITX2):c.-1422C>A SNV Uncertain Significance
 899914 rs1423855887 GRCh37: 4:111563112-111563112
GRCh38: 4:110641956-110641956
50 UPF3B NM_080632.3(UPF3B):c.758T>C (p.Ile253Thr) SNV Uncertain Significance
 284394 rs754982440 GRCh37: X:118975088-118975088
GRCh38: X:119841125-119841125

Copy number variations for Cataract from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 86882 14 67000000 106368585 Copy number cataract
2 89231 15 17000000 100338915 Copy number cataract
3 106728 17 1 11200000 Copy number cataract
Sources

Expression for Cataract

About this section
Search GEO for disease gene expression data for Cataract.
Sources

Pathways for Cataract

About this section


Pathways directly related to Cataract:

# Pathway Source
1 Defective SLC33A1 causes spastic paraplegia 42 (SPG42) Reactome 66

Pathways related to Cataract according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
1q21.1 copy number variation syndrome 74
10.09 GJA8 GJA3
Sources

GO Terms for Cataract

About this section

Biological processes related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.65 RHO GJA3 CRYGD CRYBB3 CRYAA
2 gap junction-mediated intercellular transport GO:1990349 9.46 GJA8 GJA3
3 lens development in camera-type eye GO:0002088 9.32 LIM2 GJA8 CRYGD CRYBB3 CRYAA

Molecular functions related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of eye lens GO:0005212 9.23 LIM2 CRYGD CRYBB3 CRYAA
Sources

Sources for Cataract

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....